AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1955620 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 18% calories from fat, 100 mg cholesterol/day
Number of subjects: 531
Study 7035950 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 67
Study 7035950 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate, antithymocyte globulin, and prednisone
Number of subjects: 67
Study 30813188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% BAC
Number of subjects: 24
Study 30813188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% BAC
Number of subjects: 24
Study 30813188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09% BAC
Number of subjects: 24
Study 30813188 — intervention group
Group type: COMPARATOR
Intervention: 0% BAC (placebo)
Number of subjects: 24
Study 30127596 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg
Number of subjects: 54
Study 30127596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27179724 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 8859
Study 27179724 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTE-ACS
Number of subjects: 8859
Study 27179724 — intervention group
Group type: COMPARATOR
Intervention: SIHD
Number of subjects: 8859
Study 24596459 — intervention group
Group type: EXPERIMENTAL
Intervention: IND + GLY (indacaterol 150 μg and glycopyrronium 50 μg daily)
Number of subjects: 449
Study 24596459 — intervention group
Group type: COMPARATOR
Intervention: IND + PBO (indacaterol 150 μg daily and placebo)
Number of subjects: 449
Study 22578727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy
Number of subjects: 173
Study 22578727 — intervention group
Group type: EXPERIMENTAL
Intervention: pT3b disease with positive surgical margins at the bladder neck
Number of subjects: 173
Study 22578727 — intervention group
Group type: EXPERIMENTAL
Intervention: pT3a disease (regardless of positive surgical margin location and lymph node invasion) and pT3b tumors with negative bladder neck margins
Number of subjects: 173
Study 19816216 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral upper‐body resistance exercise (RE) protocol
Number of subjects: 10
Study 19816216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral upper‐body resistance exercise (RE) protocol
Number of subjects: 10
Study 18066133 — intervention group
Group type: EXPERIMENTAL
Intervention: NG440 (a combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid)
Number of subjects: 0
Study 18066133 — intervention group
Group type: EXPERIMENTAL
Intervention: NG440
Number of subjects: 0
Study 12793922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (25%, 33%, 50%, and 67% of the respiratory cycle)
Number of subjects: 15
Study 12793922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (increasing)
Number of subjects: 15
Study 12793922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (very low <0.4 secs and very long >1.0 secs)
Number of subjects: 15
Study 12793922 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (0.4-1.0 secs)
Number of subjects: 15
Study 10210394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine
Number of subjects: 316
Study 10210394 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg tolterodine
Number of subjects: 316
Study 10210394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 7790604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 18 ppm
Number of subjects: 10
Study 7790604 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of prostacyclin (PGI2) at 4 ng.kg-1.min-1
Number of subjects: 10
Study 2088632 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-based toothpaste containing strontium acetate
Number of subjects: 0
Study 2088632 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-based toothpaste containing strontium acetate and MFP
Number of subjects: 0
Study 2088632 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available formaldehyde-containing toothpaste
Number of subjects: 0
Study 2088632 — intervention group
Group type: EXPERIMENTAL
Intervention: Diatomaceous earth/strontium chloride toothpaste
Number of subjects: 0
Study 6117536 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 39
Study 6117536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoridazine
Number of subjects: 39
Study 6117536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric response to neuroleptics
Number of subjects: 39
Study 31455710 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐based symptom management with alerts when symptom scores reach ≥4
Number of subjects: 160
Study 31455710 — intervention group
Group type: COMPARATOR
Intervention: Standard procedures for symptom management (Control)
Number of subjects: 160
Study 26445404 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front incentive payment (supermarket cash voucher of HD$50)
Number of subjects: 720
Study 26445404 — intervention group
Group type: COMPARATOR
Intervention: Delayed incentive payment (voucher sent after 1-year follow-up)
Number of subjects: 720
Study 23372361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 40
Study 23372361 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 40
Study 22368874 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduning injection plus antibiotics and basic therapy
Number of subjects: 7
Study 19828532 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 plus antiretroviral therapy (SILCAAT)
Number of subjects: 5806
Study 19828532 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 plus antiretroviral therapy (ESPRIT)
Number of subjects: 5806
Study 19828532 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone (SILCAAT)
Number of subjects: 5806
Study 19828532 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone (ESPRIT)
Number of subjects: 5806
Study 19650964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention in kindergartens (monthly activities for children and parents)
Number of subjects: 2102
Study 19650964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention in kindergartens
Number of subjects: 2102
Study 19650964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 2102
Study 15605372 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed postal questionnaire reporting urinary symptoms
Number of subjects: 488
Study 15605372 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported urinary symptoms (SI and UI)
Number of subjects: 488
Study 15605372 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported urinary symptoms (DO related symptoms)
Number of subjects: 488
Study 12060416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 12060416 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 0
Study 10543291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to benzene (1 microg x m3 air)
Number of subjects: 5421
Study 10543291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to NO2 and CO
Number of subjects: 5421
Study 10543291 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to traffic-related air pollution
Number of subjects: 5421
Study 7852670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg four times daily
Number of subjects: 212
Study 7852670 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 micrograms four times daily
Number of subjects: 212
Study 2161310 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for sample size and power calculations
Number of subjects: 0
Study 111873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 10
Study 111873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 111873 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 10
Study 12460877 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 14
Study 12460877 — intervention group
Group type: COMPARATOR
Intervention: Esmolol
Number of subjects: 14
Study 12460877 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine in low-flow POTS subgroup
Number of subjects: 14
Study 31925809 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (STA trial)
Number of subjects: 10
Study 31925809 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC trial)
Number of subjects: 10
Study 31925809 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus placebo (EXER+PLAC trial)
Number of subjects: 10
Study 31925809 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus statin (EXER+STA trial)
Number of subjects: 10
Study 29727777 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with 1st MTPJ OA
Number of subjects: 20
Study 26749529 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin (20mg)
Number of subjects: 142
Study 26749529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 25012497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori biolimus-eluting stent (BES)
Number of subjects: 9114
Study 22249833 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS-15 sequence (pseudo-randomized sequence, mean ISI of 15 s)
Number of subjects: 40
Study 22249833 — intervention group
Group type: COMPARATOR
Intervention: Standard sequence (ISI of 30 s)
Number of subjects: 40
Study 20304051 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU vitamin D3 daily for 6 months)
Number of subjects: 81
Study 20304051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not supplemented)
Number of subjects: 81
Study 18538098 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone (PS) membrane
Number of subjects: 20
Study 18538098 — intervention group
Group type: COMPARATOR
Intervention: Cellulose triacetate (CTA) membrane
Number of subjects: 20
Study 18538098 — intervention group
Group type: COMPARATOR
Intervention: Polyester‐polymer alloy (PEPA) membrane
Number of subjects: 20
Study 16044844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hitamine (enterosorbent of marine origin) combined with dietotherapy
Number of subjects: 0
Study 11828240 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g NH(4)Cl acute administration
Number of subjects: 29
Study 11828240 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with a history of stress fractures
Number of subjects: 29
Study 11828240 — intervention group
Group type: COMPARATOR
Intervention: Subjects without a history of stress fractures
Number of subjects: 29
Study 10088991 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring)
Number of subjects: 132
Study 10088991 — intervention group
Group type: COMPARATOR
Intervention: Continuation of coffee
Number of subjects: 132
Study 10088991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal coffee ingestion
Number of subjects: 132
Study 7751874 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus IFN (10 MU subcutaneously three times weekly)
Number of subjects: 106
Study 7751874 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (750 mg/m2/d by continuous infusion for 5 consecutive days followed by weekly bolus 5-FU 750 mg/m2)
Number of subjects: 106
Study 2281582 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 ml of ioversol (Optiray-320)
Number of subjects: 120
Study 2281582 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of diatrizoate (Renografin-60)
Number of subjects: 120
Study 382393 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg intramuscularly
Number of subjects: 50
Study 382393 — intervention group
Group type: COMPARATOR
Intervention: Omnopon 20 mg intramuscularly
Number of subjects: 50
Study 31723037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stable microparticle platform for oral micronutrient delivery (BMC)
Number of subjects: 0
Study 31723037 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient encapsulation (11 micronutrients including iron, iodine, zinc, vitamins A, B2, niacin, biotin, folic acid, B12, C, and D)
Number of subjects: 0
Study 31723037 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial human study of iron bioavailability from microparticles
Number of subjects: 0
Study 31723037 — intervention group
Group type: EXPERIMENTAL
Intervention: Organotypic human intestinal model
Number of subjects: 0
Study 29429177 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned neck dissection (PND) + concurrent chemoradiotherapy (CCRT)
Number of subjects: 64
Study 29429177 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 64
Study 26700214 — intervention group
Group type: EXPERIMENTAL
Intervention: H-100
Number of subjects: 22
Study 26700214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26700214 — intervention group
Group type: EXPERIMENTAL
Intervention: H-100 (after crossover from placebo)
Number of subjects: 22
Study 23852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604
Study 23852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604
Study 23852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604
Study 23852695 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Diclofenac Sustained Release (DSR) 75 mg
Number of subjects: 604
Study 23852695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab + Diclofenac Sustained Release (DSR)
Number of subjects: 604
Study 22892374 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine device
Number of subjects: 40
Study 22892374 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 40
Study 20137768 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablets (Gen‐Nifedipine extended release)
Number of subjects: 26
Study 20137768 — intervention group
Group type: COMPARATOR
Intervention: Reference tablets (Adalat XL)
Number of subjects: 26
Study 18030231 — intervention group
Group type: EXPERIMENTAL
Intervention: AtTGA stick
Number of subjects: 185
Study 18030231 — intervention group
Group type: EXPERIMENTAL
Intervention: AtTGA/AGA stick
Number of subjects: 185
Study 18030231 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA AtTGA/AGA stick
Number of subjects: 185
Study 16084881 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 55
Study 16084881 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 55
Study 11487990 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-based alcohol preventive intervention
Number of subjects: 650
Study 11487990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 650
Study 9725755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 0
Study 9725755 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.3 mg/kg
Number of subjects: 0
Study 8131256 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine malaria chemoprophylaxis
Number of subjects: 0
Study 2661232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Rocephin)
Number of subjects: 883
Study 2661232 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 883
Study 30218764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective screening program for C. difficile prior to cystectomy with prophylactic treatment using metronidazole.
Number of subjects: 766
Study 30218764 — intervention group
Group type: COMPARATOR
Intervention: Historical matched controls (no screening program).
Number of subjects: 766
Study 28179024 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-monthly albendazole treatment
Number of subjects: 0
Study 28179024 — intervention group
Group type: COMPARATOR
Intervention: Single annual albendazole treatment
Number of subjects: 0
Study 25623680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study 25623680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22799582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall of targets and mediators
Number of subjects: 49
Study 22799582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall of mediators
Number of subjects: 49
Study 22799582 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting the wrong target word
Number of subjects: 49
Study 22303641 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 190
Study 22303641 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg kg(‐1) morphine
Number of subjects: 190
Study 19050671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 368
Study 19050671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 19050671 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin quartiles
Number of subjects: 368
Study 19050671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 368
Study 16917560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/Sulbactan
Number of subjects: 102
Study 16917560 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/Clavulanate
Number of subjects: 102
Study 15331035 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail communication preference (LSE)
Number of subjects: 265
Study 15331035 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face communication preference (HSE)
Number of subjects: 265
Study 15331035 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail preference under high rejection scenarios
Number of subjects: 265
Study 14589782 — intervention group
Group type: EXPERIMENTAL
Intervention: malingerers
Number of subjects: 60
Study 14589782 — intervention group
Group type: EXPERIMENTAL
Intervention: malingerers-with-warnings
Number of subjects: 60
Study 14589782 — intervention group
Group type: EXPERIMENTAL
Intervention: warning-only
Number of subjects: 60
Study 14589782 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 60
Study 9645635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% topical metronidazole gel
Number of subjects: 113
Study 9645635 — intervention group
Group type: COMPARATOR
Intervention: topical metronidazole vehicle gel (placebo)
Number of subjects: 113
Study 7836628 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (MgO)
Number of subjects: 5
Study 7836628 — intervention group
Group type: COMPARATOR
Intervention: Control studies (no magnesium supplementation)
Number of subjects: 5
Study 2841172 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate ophthalmic ointment (5 mg/g and 10,000 units/g)
Number of subjects: 0
Study 2841172 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic ointment (1%)
Number of subjects: 0
Study 2841172 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both treatments
Number of subjects: 0
Study 29660670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt group (passive tilting added to standardized rehabilitation therapy)
Number of subjects: 145
Study 29660670 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized rehabilitation therapy alone)
Number of subjects: 145
Study 29660670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt group
Number of subjects: 145
Study 29660670 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study 28176423 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical foot massage
Number of subjects: 60
Study 28176423 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 60
Study 28176423 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 60
Study 25841654 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced CBM-errors (targeting cognitive errors plus prospective cognition)
Number of subjects: 80
Study 25841654 — intervention group
Group type: COMPARATOR
Intervention: Standard CBM-errors (targeting cognitive errors without prospective cognition)
Number of subjects: 80
Study 23529918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET) + Antihypertensive Drugs (ADs)
Number of subjects: 120
Study 23529918 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive Drugs (ADs) alone
Number of subjects: 120
Study 21440882 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculopuncture and ultralow‐power laserpuncture
Number of subjects: 0
Study 21440882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 0
Study 18326592 — intervention group
Group type: EXPERIMENTAL
Intervention: TFAs from natural sources (11-12 g/d, approximately 5% of daily energy)
Number of subjects: 46
Study 18326592 — intervention group
Group type: COMPARATOR
Intervention: TFAs from industrially produced sources
Number of subjects: 46
Study 16566972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and prostatic massage (group 1: n = 17)
Number of subjects: 81
Study 16566972 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (group 2: n = 20)
Number of subjects: 81
Study 16566972 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and prostatic massage (group 3: n = 25)
Number of subjects: 81
Study 16566972 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (group 4: n = 19)
Number of subjects: 81
Study 11902250 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH) at 2 L/hr for 48 hrs
Number of subjects: 24
Study 11902250 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemofiltration)
Number of subjects: 24
Study 11902250 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 24
Study 10458528 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation with the aid of an FHR meter
Number of subjects: 30
Study 10458528 — intervention group
Group type: COMPARATOR
Intervention: Auscultation by counting alone
Number of subjects: 30